Jan 24, 2025 | Press Releases
HDT Bio’s LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ — MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio’s proprietary self-amplifying replicon RNA...
Sep 17, 2024 | Press Releases, Uncategorized
HDT bio’s Rapid-Response Roadmap for RNA vaccines (R4) project granted a five-year subaward for $2M per year SEATTLE, Sept. 17, 2024 /PRNewswire/ — HDT Bio Corp., a clinical-stage biopharmaceutical company specializing in advanced RNA vaccine technologies,...
Aug 7, 2024 | Press Releases
Self-amplifying RNA vaccine, delivered by cationic nanocarrier (LION™) elicits neutralizing antibody responses in mice and nonhuman primates and protects mice from enterovirus D68 (EV-D68) respiratory infection and resulting disease in mice. Findings published in the...
Nov 16, 2023 | Press Releases
SEATTLE, Nov. 16, 2023 /PRNewswire/ — HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced its participation at the World Vaccine Congress West Coast 2023 in Santa...
Oct 31, 2023 | Press Releases
SEATTLE, Oct. 31, 2023 /PRNewswire/ — HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced that Dr. Steven Reed, Chief Executive Officer of HDT Bio, will present at...
Oct 4, 2023 | Press Releases
Award will fund the development of HDT-201, HDT Bio’s thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate HDT-201 investigated as pre-exposure or post exposure prophylactic in high-risk situations SEATTLE, Oct. 4, 2023...
